Ambry’s digital CARE Program TM improves patient care by expanding access to carrier screening and non-invasive prenatal testing (NIPT). ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (Ambry), a ...

LEXINGTON, KY, UNITED STATES, March 11, 2026 / EINPresswire.com / — The Child Neurology Foundation (CNF) today announced Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), ...

IRVINE, CA (November 12, 2004) – AMBRY GENETICS, a leading genetic testing company, announced it has added a new research test to its product line. Ambry Genetics is offering ADRB2 sequencing, ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare by ...

The Ambry CARE Program® brings accurate, personalized breast cancer risk assessments directly into clinical workflows helping direct patients at high risk for breast cancer to seek additional ...

New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predisposition. PALB2 is one of the ...

TOKYO (Reuters) - Konica Minolta Inc <4902.T> said it was purchasing U.S. diagnostics company Ambry Genetics in a deal valued at up to $1 billion - an acquisition that marks a strategic shift for the ...

The first data released today are anonymized, aggregated data of 10,000 human genomes (exomes) focused on hereditary breast and ovarian cancer. Ambry Genetics has already identified 10-fold more genes ...